A phase IIa, multi-center, randomized, double-blind, vehicle-controlled study to determine antipsoriatic efficacy and safety of topical CEP-701 (lestaurtinib) cream formulations in patients with psoriasis vulgaris.
Phase of Trial: Phase II
Latest Information Update: 26 Jul 2011
At a glance
- Drugs Lestaurtinib (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Therapeutic Use
- 26 Jul 2011 New trial record